Thyronamines: novel bioactive metabolites of thyroid hormone

Case ID:
0674
Web Published:
7/22/2015
Description:

NOVEL BIOACTIVE METABOLITES OF THYROID HORMONE:

A SAFE AND EFFECTIVE TREATMENT FOR DISEASE

OHSU Technology 0674

 

Researchers at Oregon Health & Science University and University of California, San Francisco discovered and validated a new class of thyroid hormone metabolites. The most potent of these, 3-iodothyronamine, has been shown in animal studies to completely switch fuel utilization away from carbohydrates and toward lipids. Compounds in this class include both selective agonists and antagonists of the G-protein coupled receptor, TAAR-1. Ex vivo studies demonstrate that the compounds significantly increase cardiac output and decrease systemic vascular resistance with no change in heart rate or blood pressure, therefore demonstrating proof of concept for treatment of congestive heart failure. Further, a broad spectrum of in vivo studies with the thyronamines positively supports their use for treating thyroid hormone disorders, hyper- and hypoglycemia, obesity, and depression and mood disorders.

 

 

                                                       

INVENTOR PROFILE:

Thomas S. Scanlan, PhD, is the Program Director in Chemical Biology and Professor of Physiology and Pharmacology. Dr. Scanlan’s research focuses on developing and understanding the molecular basis of thyroid hormones in a multidisciplinary approach that involves synthetic chemistry, biochemistry, cell biology, and ultimately physiology.

 

David Grandy, PhD, is Professor of Physiology and Pharmacology. Dr. Grandy’s research focuses on complex signaling systems, particularly G protein-coupled receptor proteins with a combination of molecular, cellular, and behavioral approaches to explore opiate tolerance and drug dependence.

 

Patent Status:

Issued patent  7,321,065

 

Licensing Opportunity

OHSU Technology 0674 is available for exclusive licensing.

 

Relevant Publications:

Scanlan T, Suchland K, Hart M, Chiellini G, Huang Y, Kruzich P, Frascarelli S, Crossley D, Bunzow J, Ronca-Testoni S, Lin E, Hatton D, Zucchi R, Grandy D,  3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone, Nat. Med. 10 (6): 638–42 (2004).

Patent Information:
Category(s):
Therapeutics
For Information, Contact:
Michele Gunness
Senior Technology Development Manager
Oregon Health & Science University
(503) 494-8200
gunnessm@ohsu.edu
Inventors:
Thomas Scanlan
David Grandy
James Bunzow
Katherine Suchland
Matthew Hart
Edwin Tan
Mononori Miyakawa
Keywords:
Therapeutics
Therapeutics - Cardiology
Therapeutics - Endocrine
© 2018. All Rights Reserved. Powered by Inteum